Skip to main content
. 2019 Jul 18;25(6):318–325. doi: 10.5761/atcs.oa.19-00128

Table 2. Background and risk factors of the patients.

JPS-16 Placebo p value

Age (years) 65.2 ± 13.9 69.2 ± 13.0 0.432
Sex 0.712
 Male 10 14
 Female 3 3
Weight (kg) 59.2 ± 11.6 60.1 ± 11.8 0.843
Obesity (BMI ≥ 25) 2 5 0.368
Cigarette smoking 0.469
 Never 3 6
 Previous 10 11
 Current 0 0
Brinkman index 306 ± 361 373 ± 442 0.661
Hypertension 9 7 0.127
Diabetes mellitus 5 6 0.858
COPD 0 1 0.373
Hemodialysis 0 1 0.374
ACEI 2 2 0.772
Restricted ventilation disorder 2 0 0.091
Obstructive ventilation disorder 2 3 0.859
Operation time (min) 333.2 ± 86.3 319.2 ± 67.5 0.622
Off-pump surgery 1 0 0.244
On-pump CABG 5 8 0.637
CPB time (min) 146.0 ± 83.5 121.1 ± 55.6 0.342
Opened pleural cavity 7 13 0.192
Disease
 Valvular disease 5 6
 IHD 6 8
 Valvular disease + IHD 2 2
 ASD 0 1

p values were calculated using the Pearson χ2 test for categorical data or the Student’s t-test for continuous data. All continuous data were expressed as mean ± SD. The definition of restricted ventilation disorder is %VC < 80%. The definition of obstructive ventilation disorder is FEV1.0% < 70%. ACEI: angiotensin-converting enzyme inhibitor; ASD: atrial septal defect; BMI: body mass index; CPB: cardiopulmonary bypass; COPD: chronic obstructive pulmonary disease; FEV%1: forced expiratory volume % in one second; IHD: ischemic heart disease; JPS-16: JPS hangekobokuto extract granules; %VC: %vital capacity; CABG: coronary artery bypass grafting